Biotech stocks are going wild, and these two could be your best bet for a bigger breakout

Keep Me Logged InBiotech is blazing higher.The IBB biotechnology ETF is on track for its best quarter in six years, adding 19 percent in a rally twice as steep as the gains on the XLV health care ETF.Craig Johnson, chief market technician at Piper Jaffray, says biotech should continue to be a healthy trade."For a lot of investors, they're trying to play catch-up at this point in time, and they're going to continue to play these risk assets," Johnson said Friday on CNBC's "Trading Nation." "We still see decent upside from here to go — perhaps about 6 percent higher from here, maybe as high as 13 percent higher."A move at the high end of that range would take the IBB back to levels not seen since August 2015."One of the names that looks pretty good to us is Regeneron," Johnson said. Here's what it means for the economy and the Federal Reserve.The stock market is entering its most bullish period of the year, according to Bespoke’s Paul Hickey.Craig Johnson of Piper Jaffray and John Petrides of Point View Wealth Management discuss why investors can trust the biotech rally with CNBC's Mike Santoli.Bespoke’s Paul Hickey outlines his bull case for March.Gina Sanchez of Chantico Global says a North Korean attack, should one occur, isn't likely to cause significant long-term market impact.Boris Schlossberg of BK Asset Management says the ISM non-manufacturing report is key to watch ahead the jobs data released Friday.